Life AI Net
首页
资讯库
计算器
目录
周刊
Hot
登录
简体中文
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
首页
资讯库
计算器
目录
周刊
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
登录
首页
资讯库
计算器
目录
More
滚动资讯
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
资讯库
搜索
搜索
最新
最旧
清除
@BioWorld
总数
1057
来源
BioWorld
搜索
--
BioWorld
2026年4月10日
Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers
BioWorld
2026年4月10日
New TRPC6/7 antagonists disclosed in Nyrada patent
BioWorld
2026年4月10日
Biologics in development outnumber small molecules for the first time
BioWorld
2026年4月10日
Regeneration in mammals is controlled by environmental conditions
BioWorld
2026年4月9日
Regeneration in mammals is controlled by environmental conditions
BioWorld
2026年4月9日
Financings for April 9, 2026
BioWorld
2026年4月9日
In the clinic for April 9, 2026
BioWorld
2026年4月9日
Other news to note for April 9, 2026
BioWorld
2026年4月9日
Regulatory actions for April 9, 2026
BioWorld
2026年4月9日
Ewha Womans University, Gachon University patent YAP1/TEAD interaction inhibitors
BioWorld
2026年4月9日
MSD discloses new HCN1/2 blockers
BioWorld
2026年4月9日
PD-1/PD-1L interaction inhibitors described in Affirma Biotech patent
BioWorld
2026年4月9日
Sidewinder’s bispecific ADC approach draws $137M series B
BioWorld
2026年4月9日
Smart contact lens delivers adaptative glaucoma therapy
BioWorld
2026年4月8日
Appointments and advancements for April 8, 2026
BioWorld
2026年4月8日
Financings for April 8, 2026
BioWorld
2026年4月8日
In the clinic for April 8, 2026
BioWorld
2026年4月8日
Other news to note for April 8, 2026
上一页
5 / 59
下一页